[Summary] Committed to serving China's precision oncology
Founded in 2015, Yuce Biotechnology is a domestic platform for integrated solutions in tumor immunodiagnosis and therapy, conducting product development, translation, and commercial promotion around its technical capabilities in neoantigen detection. The company possesses an international platform for tumor neoantigen detection and identification, a multidimensional tumor immunodetection and research platform, a professional tumor immunology bioinformatics interpretation database, and a real-world research database for tumor immunodiagnosis and treatment. Relying on internationally high-standard research and production quality systems and an experienced management and operations team, it provides clinically accessible medication guidance and dynamic monitoring detection products for tumor patients, precision medicine solutions for medical institutions and service providers, and high-quality companion diagnostics and therapeutic target development services for pharmaceutical companies.
Since its establishment, Yuce Biotechnology has completed 5 rounds of financing totaling hundreds of millions of yuan, built a third-party medical testing laboratory, and established an IVD R&D and production base in Jiangsu. Its business covers tumor clinical testing and clinical research, pharmaceutical R&D services and integrated clinical trial solutions, and companion diagnostics-in vitro diagnostic reagents (CDx-IVD). Its business spans over 40 cities and more than 400 hospitals, and it has cumulatively applied for 45 domestic and international invention patents and 56 software copyrights. In 2017, Yuce Biotechnology, together with Academician Zhan Qimin, jointly launched the domestic tumor immunotherapy real-world study "China Anti-Cancer · Tianti Program".
Yuce Biotechnology has successively obtained certifications as a National High-tech Enterprise and a Shenzhen High-tech Enterprise, and was among the first Chinese companies to join the International Neoantigen Screening Alliance in Asia. It is also one of the earliest institutions in China to provide TMB (tumor mutational burden) testing, accumulate multi-tumor immunotherapy genetic data, and conduct dynamic monitoring research on tumor immunotherapy efficacy.
Adhering to the mission of "making tumor immunotherapy more effective", Yuce Biotechnology is committed to becoming China's leading brand in precision tumor immunodiagnosis and treatment.
What does Shenzhen Yuce Biotechnology Co., Ltd. require? Who is Yuce Biotechnology hiring? Yuce Biotechnology recruitment: 销售类占比最多占70%，其次是经营管理类占30%. What education can get in at Yuce Biotechnology? 本科占比最多占60%，其次是大专占20%. High education required at Yuce Biotechnology? 硕士占20%. Work experience required at Yuce Biotechnology? 1-3年占比最多占30%，其次是3-5年占30%. Where are the job locations at Yuce Biotechnology? 深圳占比最多占40%，其次是广州占20%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
